...
首页> 外文期刊>Investigational new drugs. >Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer.
【24h】

Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer.

机译:低分子量肝素调节CXCR4和CXCL12的相互作用可抑制结肠癌的肝转移。

获取原文
获取原文并翻译 | 示例
           

摘要

Liver metastasis is the major obstacle for prolonging the survival of colon cancer patients. Low-molecular-weight heparin (LMWH), a common drug for venous thromboembolism, has displayed beneficial effects in improving the survival of cancer patients, though the mechanism remains unclear. This study aimed to investigate the effects of LMWH on hepatic metastasis of colon cancer and its underlying molecular mechanism by targeting the interaction of the chemokine receptor CXCR4 and its ligand CXCL12 (formerly known as stromal cell-derived factor 1α, SDF-1α), as the CXCR4-CXCL12 axis has been shown to regulate the interaction of cancer cells and stroma. Experimental results revealed that LMWH (Enoxaparin, 3500-5500 Da) inhibited the CXCL12-stimulated proliferation, adhesion and colony formation of human colon cancer HCT-116 cells that highly expressed CXCR4. Interestingly, LMWH or an anti-CXCR4 blocking antibody diminished the migrating and invading abilities of HCT116 cells stimulated by the recombinant CXCL12 protein or liver homogenates which contained endogenous CXCL12 protein. Although LMWH did not significantly inhibit the growth of subcutaneous colon tumors, it significantly suppressed the formation of hepatic metastasis established by intrasplenic injection of colon cancer cells in nude Balb/c mice and also downregulated the expression of CXCL12 in hepatic sinusoidal endothelial cells. The results suggest that LMWH inhibits the formation of hepatic metastasis of colon cancer by disrupting the interaction of CXCR4 and CXCL12, supporting that perioperative administration of LMWH may help to prevent the seeding and subsequent growth of hepatic metastases of colon cancer cells.
机译:肝转移是延长结肠癌患者生存的主要障碍。低分子量肝素(LMWH)是一种用于静脉血栓栓塞的常用药物,尽管其机制尚不清楚,但已显示出对改善癌症患者存活率的有益作用。这项研究旨在通过靶向趋化因子受体CXCR4及其配体CXCL12(以前称为基质细胞衍生因子1α,SDF-1α)的相互作用来研究LMWH对结肠癌肝转移的影响及其潜在的分子机制。 CXCR4-CXCL12轴已被证明可调节癌细胞与基质的相互作用。实验结果表明,LMWH(Enoxaparin,3500-5500 Da)抑制了CXCL12刺激的高表达CXCR4的人结肠癌HCT-116细胞的增殖,粘附和集落形成。有趣的是,LMWH或抗CXCR4阻断抗体减弱了由重组CXCL12蛋白或含有内源性CXCL12蛋白的肝匀浆刺激的HCT116细胞的迁移和侵袭能力。尽管LMWH不能显着抑制皮下结肠肿瘤的生长,但是它可以显着抑制脾脏内裸鼠Balb / c小鼠脾脏注射结肠癌细胞所建立的肝转移的形成,并且还可以下调肝窦内皮细胞中CXCL12的表达。结果表明,LMWH通过破坏CXCR4和CXCL12的相互作用来抑制结肠癌肝转移的形成,支持围手术期给予LMWH可能有助于防止结肠癌肝转移的播种和随后生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号